Loading…
← CockpitCompetitor Analysis › 6849.T Nihon Kohden CorporationOpen in the cockpit ↗

Nihon Kohden Corporation6849.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Leading Japanese maker of patient monitors, ECG machines and defibrillators used in hospitals worldwide.

≈ Japan's GE Healthcare for patient monitoringMomentum neutral 57
Mkt cap
$1.55B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$6.86M
20-day average traded
Fwd P/E
18.8×
forward earnings
ROIC−WACC
+2.4 pp
WACC 5.3%
Hurdle
-7 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · JPY¥1,519
1D-2.0%
1W+1.3%
1M-8.4%
3M+2.4%
6M+2.8%
YTD-9.7%
1Y-14.8%
ATR %2.9%
52w lowhigh19.4% off high

What Nihon Kohden does

Leading Japanese maker of patient monitors, ECG machines and defibrillators used in hospitals worldwide.

Sells monitors and diagnostic equipment to hospitals, with disposables such as electrodes and sensors and service contracts keeping revenue coming after the machine is installed. Japanese hospital spending sets the base, and overseas markets, including the US, are a growing share.

In one line: Japan's GE Healthcare for patient monitoring.

Products and services

  • Patient monitors
  • ECG/diagnostic equipment
  • Defibrillators (AEDs)
  • Clinical information systems

Customers

  • Hospitals
  • Emergency medical services
  • Clinics

Where it sits in the supply chain

  • Health care
  • Medical devices
  • Patient monitors, ECG, defibrillators…

What could go right

  • Global hospital equipment replacement demand

What could go wrong

  • Hospital capex cyclicality
  • Currency (yen) sensitivity

Moat: narrow (installed base, brand, regulatory licence). Leading share and installed base in Japanese hospital patient monitoring, expanding overseas on brand trust.

Headquarters: Tokyo, Japan · Founded: 1951 · Employees: 6,116

Named competitors

Nihon Kohden at a glance

Size Nihon Kohden (6849.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.55B, the 566th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,519 on 18 Nov 2026.

Performance Over six months the shares gained 2.8%, against -2.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue fell 0.2% over the last twelve months (peer median +8.6%); the operating margin is 7.0% (peer median 9.7%).

Valuation It trades at 18.8× forward earnings against a peer median of 24.5× (7th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.4 points above its cost of capital (5.3% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20266849.T 102Peer median 100
Six months, rebased to 100: Nihon Kohden against the median of its 20 peers (local-currency closes).

Nihon Kohden financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥230B¥235B¥225B¥222B¥207B
Revenue growth—+4%+2%+7%—
Gross profit¥122B¥118B¥114B¥109B¥103B
EBITDA¥22.4B¥24.6B¥24.9B¥23.4B¥24.9B
Net income¥12.0B¥14.5B¥14.1B¥17.0B¥17.1B
Free cash flow¥22.6B¥15.3B¥8.16B¥12.0B-¥9.97B
Capital expenditure¥7.84B¥7.86B¥8.71B¥4.79B¥8.26B
Total debt¥23.7B¥25.2B¥26.1B¥654M¥441M

Quarterly statements and history in the cockpit →

Nihon Kohden competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%688016ENOVVITR6885313010876699BFLYELN300049300298PRCT8086INSPKMTSCNMDEMBLA301363LMATCHEMM6849.T6-month return →1-month return →
Up and to the right = strong over both horizons. Nihon Kohden is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×688016ENOVVITR6885313010876699ELN3000493002988086INSPXRAY301363LMATCHEMM6849.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nihon Kohden is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688016ENOVVITR3010876699ELN300049300298INSPCNMDEMBLA301363CHEMM6849.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nihon Kohden is the large dot.

Nihon Kohden competitors and peer comparison

Head to head with its named competitors (6849.T vs GEHC vs 6960.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Nihon Kohden 6849.T$1.55B+3%0%7%18.8×-3.5%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%
Fukuda Denshi 6960.T$1.84B+4%0%19%15.4×-1.6%

How Nihon Kohden compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nihon Kohden against its 20 peers (data as of 18 Nov 2026)
Measure6849.TPeer medianRank in peer set
1-month return-8.4%-0.1%6th lowest of 21
6-month return+2.8%-2.3%9th highest of 21
Distance from 52-week high-19.4%-26.7%8th highest of 21
Revenue growth (TTM)-0.2%+8.6%4th lowest of 21
Operating margin7.0%9.7%10th lowest of 21
Forward P/E18.8×24.5×7th cheapest of 18
Growth the price implies (Req g, 7 yrs)-3.5%11.2%least demanding of 16
Growth delivered (Del g)+3.3%+12.9%3rd lowest of 16
Hurdle (Req g minus delivered)-6.8 pp-0.3 pp8th least demanding of 16
ROIC minus cost of capital+2.4 pp-0.1 pp10th highest of 21
EV / EBITDA9.4×14.0×4th cheapest of 11
Net debt / EBITDA-1.6×0.8×5th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%

Questions

Who are Nihon Kohden's main competitors?
Named competitors: GE HealthCare (GEHC), Philips (private or unlisted), Fukuda Denshi (6960.T). The cockpit's measured peer set (industry) also includes Shanghai MicroPort Endovascular MedTech (688016.SS), Enovis (ENOV), Vitrolife (VITR.ST), Wuxi Unicomp Technology (688531.SS), Cofoe Medical Technology (301087.SZ), Angelalign Technology (6699.HK).
Is Nihon Kohden expensive compared with its peers?
On forward p/e it trades at 18.8× against a peer median of 24.5×, 7th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Nihon Kohden stock performed?
Over six months to 18 Nov 2026 the shares returned +2.8% against -2.3% for the median peer; over one year -14.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.